Controversies in the treatment of hypercholesterolemia in the elderly: Who should be treated and how?

American Journal of Geriatric Cardiology

Volumn 10, Issue 3, 2001, Pages 152-158

  Miura, D S ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

AGED; AGING; ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; EDUCATION PROGRAM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SIDE EFFECT;

EID: 0035034552     PISSN: 10767460     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1076-7460.2001.00003.x     Document Type: Article

References (31)

1. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
2. Dyslipidemia and coronary artery disease in the elderly
3. Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein >125 mg/dl
4. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years
5. Hypercholesterolemia: Is lipid-lowering worthwhile for older patients?
6. High blood cholesterol in elderly men and the excess risk for coronary heart disease
7. The challenge of the health care delivery to the elderly patient with cardiovascular disease: Demographic, epidemiologic, fiscal and health policy implications
8. Aging, mortality, and the compression of mortality
9. Coronary heart disease: Stable and unstable syndromes
10. Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly
11. Referral patterns and exercise response in the rehabilitation of female coronary patients ages >62 years
12. Are we biased in our approach to treating elderly patients with heart disease?
13. pat patterns of practice in acute myocardial infarction 1988-1989: Comparison of younger versus older patients
14. Clinical guideline, Part 1. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults
15. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
16. Cholesterol lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Finding from the Scandinavian Simvastatin Survival Study (4S)
17. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
18. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
20. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
21. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
22. An overview of trials of cholesterol lowering and risk of stroke
23. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program
24. Cost effectiveness of assessment and management of risk factors
25. Matching intensity of intervention with risk for coronary events: Targets for LDL-C, HDL-C, and other risk factors
26. The cost effectiveness of programs to lower serum cholesterol
27. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease. Forecasting the incremental benefits of preventing coronary and cerebrovascular events
28. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
29. Prediction of coronary, heart disease using risk factor categories
30. Time trends in the use of cholesterol-lowering agents in older adults. The cardiovascular heart study
31. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics